BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 01, 2010
 |  BioCentury  |  Emerging Company Profile

Shield: Armoring Iron for IBD

Shield is developing what could be the first oral iron therapy for anemia in IBD

In most anemia patients, oral iron therapies such as ferrous salts are usually tried first, but gastrointestinal side effects such as diarrhea and constipation make them inappropriate for patients with inflammatory bowel disease. Shield Holdings AG believes its ST10-021 could be the first oral iron therapy for these patients because it does not have the side effects.

The company was to announce this week that it has granted AOP Orphan Pharmaceuticals AG rights to ST10-021 in central and eastern Europe and the Middle East. In return, AOP will invest €3 million ($4.2 million) for a 12% stake in Shield.

Because existing oral irons are contraindicated for IBD, IV iron therapies are the first choice. But the IV treatments require multiple visits to the hospital, making them both inconvenient and expensive.

For example, Venofer iron sucrose from Fresenius Medical Care AG & Co. KGaA and its partner Vifor Pharma, a unit of Galenica Ltd., requires five visits to the hospital over a two-week...

Read the full 817 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >